BioCentury | Dec 15, 2003
Finance

Ebb & Flow

...Corp. (11.1%). The Chairman and CEO is Edward Erickson, who formerly ran cancer delivery play DepoTech...
BioCentury | Jul 7, 2003
Finance

Helping push open a window

...Organogenesis raises $15.2M (units)I8/1/95 - Cephalon (CEPH) raises $67.5M (follow-on) - deal opens windowJ9/29/95 - DepoTech...
BioCentury | Sep 17, 2001
Regulation

Accelerated approvals

...both paclitaxel- and platinum-based chemotherapy Reduction in tumor size Marketed under accelerated approval DepoCyt 04/01/99 DepoTech...
BioCentury | Apr 10, 2000
Finance

A Bloody Mary hits the spot

...million ($21.2 million) to make a contingent payment of £13.1 million to former shareholders of DepoTech...
BioCentury | Apr 10, 2000
Company News

Amgen, SkyePharma deal

...DepoFoam technology for use with its product. SKP obtained DepoFoam through its 1999 acquisition of DepoTech...
...see BioCentury, March 15, 1999), and the AMGN collaboration triggered a final contingent payment to DepoTech...
BioCentury | Apr 4, 2000
Company News

SkyePharma DepoFoam deal with Amgen

...DepoTech . Tuesday's deal with AMGN triggers a 13.3 million ($20.1 million) payment to former DepoTech...
BioCentury | Jan 4, 2000
Finance

1999 M&A activity

...Technologies Pentose $45.0 Sigma-Aldrich Genosys $39.5 Proteus Therapeutic Antibodies $39.0 Palatin Molecular Biosystems $32.5 SkyePharma DepoTech...
BioCentury | Jun 28, 1999
Company News

Roche Molecular Systems Inc. management update

...VP of regulatory and clinical affairs, formerly SVP of regulatory affairs and quality assurance at DepoTech Corp....
BioCentury | Apr 12, 1999
Clinical News

SkyePharma regulatory update

...to DepoTech's acquisition by SKP will receive 1.06 SKP ADS for every 10 shares of DepoTech...
...condition of the approval, which was based on the surrogate marker of complete response rate, DepoTech...
BioCentury | Apr 12, 1999
Strategy

The proof is in the monetizing

...will have the opportunity to prove it got a bargain in its 1998 acquisition of DepoTech Corp....
...$51.1 million in its ADSs for DepoTech, including a milestone of about $16 million to DepoTech...
...a macromolecule program would trigger a remaining milestone to DepoTech shareholders worth about $11 million. DepoTech's...
Items per page:
1 - 10 of 89
BioCentury | Dec 15, 2003
Finance

Ebb & Flow

...Corp. (11.1%). The Chairman and CEO is Edward Erickson, who formerly ran cancer delivery play DepoTech...
BioCentury | Jul 7, 2003
Finance

Helping push open a window

...Organogenesis raises $15.2M (units)I8/1/95 - Cephalon (CEPH) raises $67.5M (follow-on) - deal opens windowJ9/29/95 - DepoTech...
BioCentury | Sep 17, 2001
Regulation

Accelerated approvals

...both paclitaxel- and platinum-based chemotherapy Reduction in tumor size Marketed under accelerated approval DepoCyt 04/01/99 DepoTech...
BioCentury | Apr 10, 2000
Finance

A Bloody Mary hits the spot

...million ($21.2 million) to make a contingent payment of £13.1 million to former shareholders of DepoTech...
BioCentury | Apr 10, 2000
Company News

Amgen, SkyePharma deal

...DepoFoam technology for use with its product. SKP obtained DepoFoam through its 1999 acquisition of DepoTech...
...see BioCentury, March 15, 1999), and the AMGN collaboration triggered a final contingent payment to DepoTech...
BioCentury | Apr 4, 2000
Company News

SkyePharma DepoFoam deal with Amgen

...DepoTech . Tuesday's deal with AMGN triggers a 13.3 million ($20.1 million) payment to former DepoTech...
BioCentury | Jan 4, 2000
Finance

1999 M&A activity

...Technologies Pentose $45.0 Sigma-Aldrich Genosys $39.5 Proteus Therapeutic Antibodies $39.0 Palatin Molecular Biosystems $32.5 SkyePharma DepoTech...
BioCentury | Jun 28, 1999
Company News

Roche Molecular Systems Inc. management update

...VP of regulatory and clinical affairs, formerly SVP of regulatory affairs and quality assurance at DepoTech Corp....
BioCentury | Apr 12, 1999
Clinical News

SkyePharma regulatory update

...to DepoTech's acquisition by SKP will receive 1.06 SKP ADS for every 10 shares of DepoTech...
...condition of the approval, which was based on the surrogate marker of complete response rate, DepoTech...
BioCentury | Apr 12, 1999
Strategy

The proof is in the monetizing

...will have the opportunity to prove it got a bargain in its 1998 acquisition of DepoTech Corp....
...$51.1 million in its ADSs for DepoTech, including a milestone of about $16 million to DepoTech...
...a macromolecule program would trigger a remaining milestone to DepoTech shareholders worth about $11 million. DepoTech's...
Items per page:
1 - 10 of 89